USE OF DIFFERENT DRUG THERAPY REGIMENS FOR HYPERTENSION

Download full text PDF
DOI: https://doi.org/10.29296/25419218-2018-01-06
Issue: 
1
Year: 
2018

M.S. Soboleva, PhD Far Eastern State Medical University; 35, Muravyev-Amursky St., Khabarovsk 680000, Russian Federation

Introduction. Cardiovascular diseases remain one of the most common conditions; among them hypertension is encountered more frequently. In the Russian Federation, the incidence of diseases of the circulatory system has almost doubled over 15 years. Objective: to analyze the use of the current Russian hypertension therapy standards in clinical practice. Material and methods. The investigation object was reviews of Russian publications dedicated to the analysis of the pharmaceutical market and to the prescriptions for cardiac medications in the Russian Federation. Results. Current Russian federal and regional multicenter investigations of the pharmaceutical market, medical prescriptions, and indicators for sales of antihypertensive drugs from top 5 therapeutic classes and variants of their combinations are analyzed. There are especially commonly prescribed drugs in each group. Angiotensin-converting enzyme inhibitors are most popular. The specialists’ preferences for angiotensin II receptor blockers and combined therapy regimens have changed over the last decade. Co-administration of 2, 3 or more drugs to one patient is noted to come into practice much more frequently. Conclusion. In practice, specialists approach the therapy of hypertension in accordance with the current medical standards, but may vary slightly with the stage of medical care and their preferences.
Keywords: 
hypertension
drug therapy
therapeutic classes
pharmaceutical market
clinical trials
medical prescriptions
References: 
  1. Zabolevaemost` naseleniya po osnovnym klassam bolezney. Federal`naya sluzhba gosudarstvennoy statistiki. [E`lektronnyy resurs]. Rezhim dostupa: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/healthcare/#
  2. Nikolaev N. Pacientoorientirovannaya antigipertenzivnaya terapiya: klinicheskie rekomendacii dlya prakticheskih vrachey. Vrach, 2016; 4: 82–85.
  3. Bayda A., Pozdnyakova O., Bayda K., Peregudova L. Troynaya fiksirovannaya kombinaciya antigipertenzivnyh preparatov pri arterial`noy gipertenzii. Vrach, 2017; 6: 38–40.
  4. Koe`fficienty smertnosti po osnovnym klassam prichin smerti. Federal`naya sluzhba gosudarstvennoy statistiki. [E`lektronnyy resurs]. Rezhim dostupa: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/demography/#
  5. Voroncov S., Makarova I., Shumkina M. Arterial`naya gipertenziya i hronicheskaya bolezn` pochek – faktory povyshennogo riska formirovaniya kognitivnyh narusheniy. Vrach, 2016; 12: 15–17.
  6. Duma S., Shherbakova L. Rannie kognitivnye narusheniya u molodyh pacientov s arterial`noy gipertenziey. Vrach, 2016; 1: 8–12.
  7. E`l`garov A., Kalmykova M., Apsheva E., E`l`garov M., Shogenova A. E`pidemiologiya arterial`noy gipertenzii u rabotayushhih zhenshhin. Vrach, 2017; 3: 18–22.
  8. Habibulina M. Terapiya u zhenshhin s arterial`noy gipertenziey i e`strogenodeficitom v pozdnem fertil`nom periode. Vrach, 2016; 4: 45–49.
  9. Veselova E.E., Zheltkevich O.V. Marketingovoe issledovanie assortimenta lekarstvennyh preparatov dlya lecheniya arterial`noy gipertenzii. Vest. Moskovskogo gosudarstvennogo oblastnogo gumanitarnogo instituta. Seriya: Mediko-biologicheskie nauki, 2014; 2: 19–24.
  10. Uvarova Yu. Rynok serdechno-sosudistyh preparatov v Rossii. Remedium, 2010; 4: 23–7.
  11. Oganov R.G., Timofeeva T.N., Koltunov I.E. i dr. E`pidemiologiya arterial`noy gipertonii v Rossii. Rezul`taty federal`nogo monitoringa 2003–2010 g.g. Kardiovaskulyarnaya terapiya i profilaktika, 2011; 10 (1): 9–13.
  12. Leonova M.V., Belousov Yu.B., Shteynberg L.L. i dr. Rezul`taty farmakoe`pidemiologicheskogo issledovaniya arterial`noy gipertonii «PIFAGOR IV» (opros pacientov s arterial`noy gipertoniey). Sistemnye gipertenzii, 2015; 3 (12): 11–8.
  13. Boycov S.A., Balanova Yu.A., Shal`nova S.A. i dr. Arterial`naya gipertoniya sredi lic 25–64 let: rasprostranennost`, osvedomlennost`, lechenie i kontrol`. Po materialam issledovaniya E`SSE. Kardiovaskulyarnaya terapiya i profilaktika, 2014; 13 (4): 4–14.
  14. Kushhova R.R., Avtandilov A.G., Puhaeva A.A. Rezistentnaya arterial`naya gipertenziya: osvedomlennost` vrachey i e`ffektivnost` kombinirovannoy terapii. Racional`naya farmakoterapiya v kardiologii, 2016; 12 (2): 176–9.
  15. Yankovaya T.N., Bindus O.V. Analiz ispol`zovaniya gipotenzivnyh preparatov u pacientov s arterial`noy gipertenziey II–III stepeni v ambulatorno-poliklinicheskih usloviyah. Innovacionnaya nauka, 2016; 3–4 (15): 121–3.
  16. Mamedova S.I., Salamatina L.V., Urvanceva I.A. Farmako-e`pidemiologicheskie aspekty lecheniya arterial`noy gipertenzii v Srednem Priob`e. Ural`skiy medicinskiy zhurnal, 2012;12 (104): 44–8.
  17. Salamatina A.S., Dzhuparova I.A. Razrabotka metodiki social`no-e`konomicheskogo analiza assortimenta zakupok lekarstvennyh preparatov. Medicina i obrazovanie v Sibiri, 2013; 4: 43.
  18. Omarov Sh.M., Magomedova R.G., Ataev M.G. Farmakoe`pidemiologiya lecheniya arterial`noy gipertenzii s soputstvuyushhimi hronicheskimi zabolevaniyami pecheni v usloviyah stacionara. Fundamental`nye issledovaniya, 2013; 12: 279–84.
  19. Sokolov A.V., Sadykova V.Z., Reshet`ko O.V. Analiz vrachebnyh naznacheniy antigipertenzivnoy terapii pri vypiske iz stacionara bol`nym s metabolicheskim sindromom. Sovremennaya medicina: aktual`nye voprosy, 2015; 38–9: 113–8.
  20. Davydova K.S. Problema e`kvivalentnosti vosproizvedennyh lekarstvennyh sredstv. Recept, 2011; 4: 28–33.